Squarepoint Ops LLC Grows Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Squarepoint Ops LLC lifted its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 86.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 55,668 shares of the medical equipment provider's stock after purchasing an additional 25,853 shares during the period. Squarepoint Ops LLC owned about 0.13% of AxoGen worth $917,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in AXGN. Driehaus Capital Management LLC boosted its position in AxoGen by 166.0% during the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock valued at $15,729,000 after buying an additional 595,579 shares during the period. First Light Asset Management LLC boosted its holdings in AxoGen by 10.2% during the 4th quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after acquiring an additional 416,499 shares during the period. Balyasny Asset Management L.P. purchased a new stake in AxoGen during the 4th quarter valued at about $4,943,000. Raymond James Financial Inc. bought a new position in AxoGen during the 4th quarter worth approximately $4,552,000. Finally, Russell Investments Group Ltd. increased its stake in AxoGen by 49,604.4% in the 4th quarter. Russell Investments Group Ltd. now owns 148,119 shares of the medical equipment provider's stock worth $2,441,000 after purchasing an additional 147,821 shares during the period. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Trading Up 3.6%

Shares of AXGN traded up $0.39 during trading hours on Tuesday, reaching $11.36. 462,126 shares of the company traded hands, compared to its average volume of 467,968. AxoGen, Inc. has a 12 month low of $6.57 and a 12 month high of $21.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The company's fifty day moving average price is $14.64 and its two-hundred day moving average price is $16.07. The company has a market capitalization of $517.38 million, a price-to-earnings ratio of -35.50 and a beta of 1.19.

Analyst Ratings Changes

A number of brokerages have issued reports on AXGN. Cantor Fitzgerald reissued an "overweight" rating and issued a $24.00 price target on shares of AxoGen in a report on Wednesday, March 5th. Canaccord Genuity Group reduced their price target on AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Lake Street Capital assumed coverage on AxoGen in a research report on Monday, March 17th. They issued a "buy" rating and a $30.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $22.20.

Insider Transactions at AxoGen

In other AxoGen news, insider Erick Wayne Devinney sold 15,111 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the transaction, the insider now owns 217,762 shares of the company's stock, valued at approximately $3,810,835. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joseph A. Tyndall sold 20,062 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total transaction of $224,694.40. Following the sale, the director now owns 15,345 shares in the company, valued at approximately $171,864. This trade represents a 56.66% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.78% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.